Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.

Autor: Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P, Freedman, Arnold, Neelapu, Sattva S, Nichols, Craig, Robertson, Michael J, Djulbegovic, Benjamin, Winter, Jane N, Bender, John F, Gold, Daniel P

Publikováno v: Journal of Clinical Oncology; 6/20/2009, Vol. 27 Issue 18, p3036-3043, 8p

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma

Autor: Sattva S. Neelapu, Theodore F. Logan, Izidore S. Lossos, Vincent Ribrag, Charles Herbaux, Walter J. Urba, Yoshinobu Koguchi, John M. Timmerman, Caron A. Jacobson, Satyendra Suryawanshi, John E. Godwin, Ronald Levy, Roch Houot, Andrew D. Zelenetz, Cecilia Carpio, Deanne Lathers, Gilles Salles, Jaclyn Neely, Yali Liu, Radhakrishnan Ramchandren

Publikováno v: Scientia
American Journal of Hematology
American Journal of Hematology, Wiley, 2020, 95 (5), pp.510-520. ⟨10.1002/ajh.25757⟩
American Journal of Hematology, 2020, 95 (5), pp.510-520. ⟨10.1002/ajh.25757⟩
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname

Limfoma de cèl·lules B; Urelumab Linfoma de células B; Urelumab B-cell lymphoma; Urelumab Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f29dadecdd66de9605b92ac4df56b311
https://hdl.handle.net/11351/6523

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.

Autor: Prasad R; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Rehman A; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Rehman L; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Darbaniyan F; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Blumenberg V; University Hospital, LMU Munich, Germany., Schubert ML; University Clinic Heidelberg, Germany., Mor U; Weizmann Institute of Science, Rehovot, Israel., Zamir E; German Cancer Research Center (DKFZ), Heidelberg, Germany., Schmidt S; German Cancer Research Center (DKFZ), Heidelberg, Germany., Hayase T; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Chia-Chi C; The University of Texas MD Anderson Cancer Center, United States., McDaniel LK; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Flores I; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Strati P; The University of Texas MD Anderson Cancer Center, United States., Nair R; The University of Texas MD Anderson Cancer Center, United States., Chihara D; The University of Texas MD Anderson Cancer Center, United States., Fayad LE; University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States., Ahmed S; The University of Texas MD Anderson Cancer Center, United States., Iyer SP; The University of Texas MD Anderson Cancer Center, United States., Wang ML; The University of Texas MD Anderson Cancer Center, United States., Jain P; The University of Texas MD Anderson Cancer Center, United States., Nastoupil LJ; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Westin JR; The University of Texas MD Anderson Cancer Center, United States., Arora R; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Turner JG; Moffitt Cancer Center, Tampa, Florida, United States., Khawaja F; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Wu R; The University of Texas MD Anderson Cancer Center, United States., Dennison JB; The University of Texas MD Anderson Cancer Center, United States., Menges M; Moffitt Cancer Center, Tampa, Florida, United States., Hidalgo-Vargas M; Moffitt Cancer Center, Tampa, Florida, United States., Reid KM; Moffitt Cancer Center, Tampa, Florida, United States., Davila ML; Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States., Dreger P; University Clinic Heidelberg, Heidelberg, Germany., Korell F; University Hospital Heidelberg, Heidelberg, Germany., Schmitt A; University Clinic Heidelberg, Germany., Tanner MR; The University of Texas MD Anderson Cancer Center, United States., Champlin RE; The University of Texas MD Anderson Cancer Center, United States., Flowers CR; The University of Texas MD Anderson Cancer Center, United States., Shpall EJ; The University of Texas MD Anderson Cancer Center, United States., Hanash S; The University of Texas MD Anderson Cancer Center, United States., Neelapu SS; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Schmitt M; University Clinic Heidelberg, Germany., Subklewe M; University Hospital, LMU Munich, Munich, Germany., Fahrmann J; The University of Texas MD Anderson Cancer Center, United States., Stein-Thoeringer C; University of Tuebingen, Tuebingen, Germany., Elinav E; Weizmann Institute of Science, Rehovot, Israel., Jain MD; Moffitt Cancer Center, Tampa, Florida, United States., Hayase E; The University of Texas MD Anderson Cancer Center, United States., Jenq RR; The University of Texas MD Anderson Cancer Center, United States., Saini NY; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Publikováno v: Blood [Blood] 2024 Oct 23. Date of Electronic Publication: 2024 Oct 23.